SanBio Company Limited Logo

SanBio Company Limited

Developing regenerative cell therapies for severe neurological disorders like brain injury and stroke.

4592 | T

Overview

Corporate Details

ISIN(s):
JP3336750009
LEI:
Country:
Japan
Address:
中央区明石町8番1号
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

SanBio Company Limited is a biotechnology firm dedicated to the research, development, production, and commercialization of regenerative cell medicines. The company focuses on creating novel treatments for severe neurological disorders, aiming to restore functions lost due to injury or disease. Its primary pipeline targets conditions affecting the central nervous system, such as chronic motor deficits resulting from traumatic brain injury and stroke. SanBio's lead product candidate, SB623 (marketed in Japan as AKUUGO®), is an allogeneic cell therapy developed to improve motor function in patients. The company leverages its proprietary technology for large-scale production to address significant unmet medical needs in neurology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 01:00
Share Issue/Capital Change
訂正臨時報告書
Japanese 31.2 KB
2025-09-12 08:31
Regulatory Filings
確認書
Japanese 7.9 KB
2025-09-12 08:31
Interim / Quarterly Report
半期報告書-第13期(2025/02/01-2026/01/31)
Japanese 230.6 KB
2025-06-13 08:45
Regulatory Filings
臨時報告書
Japanese 19.2 KB
2025-04-24 08:31
AGM Information
臨時報告書
Japanese 23.7 KB
2025-04-23 08:31
Registration Form
確認書
Japanese 8.0 KB
2025-04-23 08:31
Governance Information
内部統制報告書-第12期(2024/02/01-2025/01/31)
Japanese 21.6 KB
2025-04-23 08:30
Annual Report
有価証券報告書-第12期(2024/02/01-2025/01/31)
Japanese 1.3 MB
2025-03-17 07:30
Earnings Release
臨時報告書
Japanese 21.2 KB
2025-02-14 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 168.5 KB
2024-12-25 07:30
Regulatory Filings
臨時報告書
Japanese 19.3 KB
2024-12-02 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 112.5 KB
2024-09-17 08:02
Regulatory Filings
臨時報告書
Japanese 19.0 KB
2024-09-17 08:01
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-09-17 08:01
Interim / Quarterly Report
半期報告書-第12期(2024/02/01-2024/07/31)
Japanese 181.0 KB

Automate Your Workflow. Get a real-time feed of all SanBio Company Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SanBio Company Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SanBio Company Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Pasithea Therapeutics Corp. Logo
Developing innovative therapeutics for CNS disorders (ALS, MS) and RASopathies.
United States of America
KTTA
Passage BIO, Inc. Logo
Developing genetic medicines for severe CNS and neurodegenerative disorders.
United States of America
PASG
PAVmed Inc. Logo
A med-tech firm offering diagnostics for esophageal precancer & digital health for cancer care.
United States of America
PAVM
PepGen Inc. Logo
Biotech using an EDO platform to treat genetic neuromuscular & neurological diseases.
United States of America
PEPG
Perseus Proteomics Inc. Logo
Develops antibody drugs for cancer, provides research support, and sells diagnostic reagents.
Japan
4882
PExA AB Logo
Offers non-invasive lung liquid biopsy tech for respiratory disease research.
Sweden
PEXA B
Pharos iBio Co., Ltd. Logo
AI-powered drug development for rare and refractory diseases, focusing on oncology.
South Korea
388870
Pherecydes Pharma Logo
Develops precision phage therapy to treat resistant bacterial infections.
France
ALPHE
PhoenixBio Co.,Ltd. Logo
CRO providing humanized liver mouse models and testing services for preclinical drug development.
Japan
6190
PILA PHARMA AB Logo
Clinical-stage biopharma developing a first-in-class oral drug for diabetes and obesity.
Sweden
PILA

Talk to a Data Expert

Have a question? We'll get back to you promptly.